Search Within

Samuel Aaron Funt

Formats
  1. Meeting Abstract (70)
  2. Journal Article (59)
  3. Review (3)
  4. Correspondence (2)
  5. Editorial (1)
Groups
  1. Department of Medicine (135)
  2. Genitourinary Oncology Service (135)
  3. Solid Tumor Oncology Division (135)
  4. Weinberg Fellows (135)
  5. Department of Pathology and Laboratory Medicine (74)
  6. Surgery (60)

More Groups

People
  1. Dean Bajorin (87)
  2. Jonathan Rosenberg (71)
  3. Gopakumar Iyer (62)
  4. Hikmat Al-Ahmadie (54)
  5. Darren Feldman (47)
  6. Min Yuen Teo (46)

More People

Years
  1. 2025 (2)
  2. 2024 (19)
  3. 2023 (13)
  4. 2022 (19)
  5. 2021 (19)
  6. 2020 (22)

More Years

Publications
  1. Journal of Clinical Oncology (70)
  2. Annals of Oncology (4)
  3. Clinical Cancer Research (4)
  4. European Urology (3)
  5. JCO Precision Oncology (3)
  6. Nature Communications (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (73)
  2. Elsevier Science, Inc. (8)
  3. Nature Publishing Group (7)
  4. American Association for Cancer Research (6)
  5. Elsevier Inc. (6)
  6. Oxford University Press (5)

More Publishers

Results (135)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Defining the genetic evolution of epigenetic alterations in bladder cancer
    Meeting Abstract

    Clinton, T. N.; Wise, H.; Almassi, N.; Chavan, S. S.; Hu, W.; Gao, S. P.; Hanrahan, A.; Dason, S.; Pietzak, E. J.; Carlo, M. I.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Marker lesion study of oral FGFR inhibitor BGJ398 in patients with FGFR3-altered intermediate-risk nonmuscle-invasive bladder cancer
    Meeting Abstract

    Cha, E. K.; Iyer, G.; Funt, S. A.; Regazzi, A. M.; Francis, J.; Heinemann, M. H.; Ostrovnaya, I.; Dalbagni, G.; Bajorin, D. F.; Bochner, B. H.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Adjuvant chemotherapy with etoposide plus cisplatin for patients with pathologic stage II nonseminomatous germ cell tumors
    Journal Article

    McHugh, D. J.; Funt, S. A.; Silber, D.; Knezevic, A.; Patil, S.; O'Donnell, D.; Tsai, S.; Reuter, V. E.; Sheinfeld, J.; Carver, B. S.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Cancer susceptibility mutations in patients with urothelial malignancies
    Journal Article

    Carlo, M. I.; Ravichandran, V.; Srinavasan, P.; Bandlamudi, C.; Kemel, Y.; Ceyhan-Birsoy, O.; Mukherjee, S.; Mandelker, D.; Chaim, J.; Knezevic, A.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Pretreatment eosinophil counts (PEC) in metastatic urothelial carcinoma (mUC) treated with anti-PD1/PD-L1 checkpoint inhibitors (CPI)
    Meeting Abstract

    Mota, J. M.; Teo, M. Y.; Whiting, K.; Ostrovnaya, I.; Li, H.; Lee, C. H.; Funt, S. A.; Callahan, M. K.; Iyer, G.; Bajorin, D. F.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A pilot safety study of gemcitabine and cisplatin (GC) with atezolizumab (A) as first-line therapy in patients (pts) with metastatic urothelial cancer (mUC)
    Meeting Abstract

    Funt, S. A.; Jatwani, K.; Makris, M.; Regazzi, A. M.; Lee, C. H.; Teo, M. Y.; McHugh, D. J.; McCoy, A. S.; Hettich, G.; Wong, P.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Biomarkers of outcomes in a randomized phase II trial of first-line paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for intermediate- and poor-risk germ cell tumors (GCT)
    Meeting Abstract

    Feldman, D. R.; Hu, J. S.; Patil, S.; Reuter, V. E.; Srinivas, S.; Stadler, W. M.; Costello, B. A.; Milowsky, M. I.; Appleman, L. J.; Dorff, T. B.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Clinical features and outcomes of secondary somatic malignancy (SSM) arising from teratoma in late relapse germ cell tumor (GCT)
    Meeting Abstract

    Wong, N. C.; Dason, S.; Dean, L. W.; Isharwal, S.; Donoghue, M.; Jia, L.; Joseph, G.; Tap, W. D.; Funt, S. A.; McHugh, D. J.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Invasive urothelial cancer (iUC) with FGFR3 hotspot mutation/fusion (FGFR3+): A molecularly and clinically distinctive entity?
    Meeting Abstract

    Mota, J. M. S. C.; Teo, M. Y.; Li, H.; Balar, A. V.; Milowsky, M. I.; Funt, S. A.; Lee, C. H.; Regazzi, A. M.; Berger, M. F.; Solit, D. B.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Durable clinical benefit from combination ipilimumab (IPI) and nivolumab (NIVO) in anti-PD-1 therapy resistant, platinum resistant metastatic urothelial carcinoma (mUC)
    Meeting Abstract

    Keegan, N. M.; Funt, S. A.; Kania, B. E.; Iyer, G.; Clement, J. M.; McCoy, A. S.; Hettich, G.; Ziv, E.; Maher, C. A.; Nair, S.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save